Lipoprotein(a) Reduction in Persons with Cardiovascular Disease

Affiliations

¹ University Hospitals Birmingham, Birmingham, United Kingdom.
² Aristotle University of Thessaloniki, Thessaloniki, Greece.
³ Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain aortiz@fjd.es.

Comment

Charles J Ferro et al. N Engl J Med. 2020.

. 2020 May 21;382(21):e65.

doi: 10.1056/NEJMc2004861.

¹ University Hospitals Birmingham, Birmingham, United Kingdom.
² Aristotle University of Thessaloniki, Thessaloniki, Greece.
³ Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain aortiz@fjd.es.

No abstract available

Comment in

Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. Reply.
Tsimikas S, Karwatowska-Prokopczuk E, Xia S. Tsimikas S, et al. N Engl J Med. 2020 May 21;382(21):e65. doi: 10.1056/NEJMc2004861. N Engl J Med. 2020. PMID: 32433854 No abstract available.

Lipoprotein(a) Reduction in Persons with Cardiovascular Disease.
Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif JC, Baum SJ, Steinhagen-Thiessen E, Shapiro MD, Stroes ES, Moriarty PM, Nordestgaard BG, Xia S, Guerriero J, Viney NJ, O'Dea L, Witztum JL; AKCEA-APO(a)-LRx Study Investigators. Tsimikas S, et al. N Engl J Med. 2020 Jan 16;382(3):244-255. doi: 10.1056/NEJMoa1905239. Epub 2020 Jan 1. N Engl J Med. 2020. PMID: 31893580 Clinical Trial.